Dextera Biosciences key facts
- Developer of a biotechnology platform intended to develop new classes of protein-based therapeutics.
- It has raised $18.0M; the latest was Later Stage VC in Oct 2025.
- Notable investors include University of Toronto, University of Toronto Entrepreneurship, The Production Board, BEVC (Berkeley), QB3 — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Dextera Biosciences: the Monday email on marks, rounds and moves
Dextera Biosciences funding rounds
No funding rounds for Dextera Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Dextera Biosciences investors
8 investors are on record for Dextera Biosciences, including University of Toronto, University of Toronto Entrepreneurship, The Production Board and BEVC (Berkeley).
About Dextera Biosciences
Developer of a biotechnology platform intended to develop new classes of protein-based therapeutics. The company's platform offers new drug entities that are non-immunogenic and inherently resistant to proteolysis, vastly improving pharmacokinetics that precisely target the site of disease while remaining invisible to the rest of the body, enabling patients to receive therapeutics to recover from chronic diseases.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2008
- Employees
- 14
- Website
- dexterabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Dextera Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.